Regulatory Affairs
Global End-to-End RA Services, from Pre-Clinical and Clinical Studies to Product Launches
REGULATORY AFFAIRS

Our Responsibilities

Sinopep's Regulatory Affairs (RA) team works closely with all relevant functional organizations to provide global end-to-end RA services to our partners, from pre-clinical and clinical studies to product launches, including regulatory strategy consulting, technical review, dossier preparation and submission, as well as communication with regulatory agencies. The core RA team members have at least 15 years of drug registration experience, are familiar with the regulations and technical requirements of FDA, NMPA, EDQM, PMDA, etc.

Our well-trained RA staff are very familiar with different electronic submission systems in various countries and regions.

Inspection History

Since 2014, Sinopep’s GMP manufacturing facilities have successfully passed four (4) inspections conducted by the U.S. FDA, demonstrating our strong commitment to global regulatory compliance and product quality. In addition to these FDA audits, Sinopep has also undergone inspections by the Korean MFDS and has successfully completed 20 regulatory audits conducted by the NMPA in China.
Date Inspected Product Inspection Type Result
Apr 2014 Peptide API FDA CCMP Pass
Apr 2016 Peptide API FDA CCMP Pass
Jan 2019 Routine Inspection FDA CCMP Pass
Nov 2023 Small Molecule & Peptide API MFDS CCMP Pass
Sep 2024 Routine Inspection (Unannounced Inspection) FDA CGMP Pass
July 2025 Semaglutide & Liraglutide ANVISA CGMP Pass

Regulatory Experience

Over the years, Sinopep has filed over 100 dossiers to regulatory agencies such as FDA, NMPA, EDQM and PMDA covering ANDA, DMF, CEP and VMF submissions. There has been no delay or failure on deficiency response in any of our filings. Today, our APls and pharmaceutical products have been successfully marketed in over 40 countries.

100+ Dossiers filed to regulatory agencies
40+ APIs or Pharmaceutical Products Marketed

DMF Filing Status (US FDA)

Submission DMF No. Registration Status
Liraglutide 34104 FA Letter received from US-FDA
Semaglutide 36273 FA Letter received from US-FDA
Tirzepatide 39465 US DMF was submitted in 2024
Eptifibatide 23786 Approved by FDA
Bivalirudin 32281 Approved by FDA
Lanreotide Acetate 29693 Approved by FDA
Octreotide Acetate 29710 Approved by FDA
Fulvestrant 33902 Approved by FDA
Cetrorelix acetate 35171 FA Letter received from US-FDA
Desmopressin Acetate 37799 US DMF was submitted in Dec. 2022
Oseltamivir Phosphate 33907 FA Letter received from US-FDA

DMF Filing Status (NMPA)

Submission DMF No. Registration Status
Liraglutide Y20220000633 Under technical review
Semaglutide Y20220001086 Under technical review
Octreotide Acetate Y20180001746 Approved by related authority
Bivalirudin Y20190000290 Approved by related authority
Eptifibatide Y20180001360 Approved by related authority
Fulvestrant Y20200001489 Approved by related authority
Alagliptin benzoate Y20180000506 Approved by related authority
Oseltamivir Phosphate Y20200000736 Approved by related authority
Albuvirtide Y20200001298 Approved by related authority
Thymalfasin Y20170001373 Approved by related authority
Desmopressin Acetate Y20220001250 Under technical review
Cetrorelix acetate Y20220000567 Under technical review
Epalrestat Y20220001175 Under technical review
Atorvastatin calcium Y20210001031 Under technical review
Sodium Picosulfate Y20220000698 Under technical review
NEW HEIGHTS

Start Your Journey with Sinopep

Comprehensive GMP manufacturing and formulation capabilities to support your projects across all stages—from early discovery and late-phase development through to full commercialization.

Contact Us